Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1D | P28221 | 13/20 | 0.49 |
| ▸ | HTR1B | P28222 | 11/20 | 0.49 |
| ▸ | HTR1A | P08908 | 3/20 | 0.49 |
| ▸ | HTR1F | P30939 | 2/20 | 0.49 |
| ▸ | RORC | P51449 | 1/20 | 0.46 |
| ▸ | HTR6 | P50406 | 2/20 | 0.44 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8723893 | 1.00 | HTR1D (0.49) | HTR1DHTR1BHTR1AHTR1FRORC | |
| SCHEMBL8381537 | 0.93 | HTR1D (0.47) | HTR1DHTR1BHTR1AHTR1FRORC | |
| SCHEMBL8720670 | 0.93 | HTR1D (0.49) | HTR1DHTR1BHTR1AHTR1FRORC | |
| SCHEMBL8382857 | 0.91 | HTR1D (0.48) | HTR1DHTR1BHTR1AHTR1FRORC | |
| SCHEMBL7489592 | 0.86 | HTR1D (0.54) | HTR1DHTR1BHTR1AHTR1FRORC | |
| SCHEMBL8721064 | 0.86 | HTR1D (0.48) | HTR1DHTR1BHTR1AHTR1FRORC | |
| SCHEMBL8721860 | 0.85 | HTR1D (0.49) | HTR1DHTR1BHTR1AHTR1FSLC6A4 | |
| SCHEMBL7489363 | 0.85 | HTR1D (0.52) | HTR1DHTR1BHTR1AHTR1FRORC | |
| SCHEMBL30908936 | 0.85 | HTR1D (0.52) | HTR1DHTR1BHTR1AHTR1FRORC | |
| SCHEMBL8721021 | 0.83 | HTR1D (0.47) | HTR1DHTR1BHTR1AHTR1FRORC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260125645-A1 | METHODS AND PHARMACOLOGICAL AGENTS FOR INCREASING EXPANSION, ENGRAFTMENT OR IMMUNE OUTPUT OF HUMAN HEMATOPOIETIC STEM CELLS IN TRANSPLANTATION AND DISEASE SETTINGS | VALORISATION HSJ LP (CA) | 2026-05-07 | — | — | US | disclosed |
| WO-2024073845-A1 | METHODS AND PHARMACOLOGICAL AGENTS FOR INCREASING EXPANSION, ENGRAFTMENT OR IMMUNE OUTPUT OF HUMAN HEMATOPOIETIC STEM CELLS IN TRANSPLANTATION AND DISEASE SETTINGS | VALORISATION HSJ, LIMITED PARTNERSHIP (CA) | 2024-04-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260125645-A1 | METHODS AND PHARMACOLOGICAL AGENTS FOR INCREASING EXPANSION, ENGRAFTMENT OR IMMUNE OUTPUT OF HUMAN HEMATOPOIETIC STEM CELLS IN TRANSPLANTATION AND DISEASE SETTINGS | HTR1F, HTR1A, HTR1D | HTR1D 3/4885HTR1B 4/4885HTR1A 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.